In the context of BC treatment, the small molecule CPSI-1306 (isoxazoline drug), which has demonstrated the ability to suppress MIF’s oncogenic activity (184), holds promise as a non-toxic, well-tolerated therapy. Here, MIF is linked to breast cancer.